CD4 and breast cancer: Previously, we have demonstrated that thymic stromal lymphopoietin (TSLP), an epithelium-derived cytokine and a master regulator of allergic inflammation in barrier organs (Divekar and Kita, 2015; Ziegler, 2012), blocks breast cancer development through the activation of CD4+ T cells (Demehri et al., 2016).